Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03552471
Title Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center

endometrial cancer

peritoneum cancer

fallopian tube cancer

ovarian cancer


Mirvetuximab Soravtansine + Rucaparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.